The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | The safety and efficacy of HBI0101 for the treatment of R/R myeloma
In this video, Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, discusses results from a study evaluating the safety and efficacy of HBI0101, a novel academic CAR-T, in patients with relapsed/refractory (R/R) multiple myeloma. Dr Lebel summarizes the safety profile of this agent, as well as the response rates, rates of measurable residual disease (MRD) negativity, and progression-free survival (PFS) observed. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
